Chronic Hepatitis C
Conditions
Brief summary
A pilot feasibility study of a small randomized controlled trial (RCT) comparing a video-conferencing cognitive behavioral coping skills (VC-CBCS) group to standard of care (SC) for symptomatic patients previously diagnosed with chronic hepatitis C to evaluate feasibility, patient satisfaction and differences in symptoms, quality of life and liver markers.
Detailed description
This is a pilot feasibility study of a small randomized controlled trial (RCT) to evaluate a cognitive behavioral coping skills (CBCS) delivered via videoconferencing, referred to as the VC-CBCS compared to standard of care (SC). The study included a representative sample of 32 symptomatic patients who have/had chronic hepatitis C. Patients (n=32) were randomized in a 1:3 ratio to (1) standard of care (SC) or (2) to participate in 14, two hour VC-CBCS sessions. Four groups of patients were randomized and consisted of 7-9 patients each. The groups were as follows: * Group 1: 7 patients with 5 randomized to VC-CBCS and 2 to SC; * Group 2: 9 patients with 7 randomized to VC-CBCS and 2 to SC; * Groups 3 and 4: 8 patients each with 6 randomized to VC-CBCS and 2 to SC each group. Each wave of VC-CBCS patients formed a group to join the Group Facilitator via a WebEx platform on a weekly basis using iPads from their homes. The telehealth intervention provided group-based education, skills and practices involving stress management, coping with symptoms, and support for healthy lifestyle changes. The researchers examined: (1) the feasibility of delivering a group intervention via telehealth technology remotely using iPads, (2) participant satisfaction with the intervention, and (3) whether differences are observed in several outcomes between the two conditions on quality of life, physical and mental symptoms, and liver markers. Participants completed patient-reported outcome (PRO) surveys at four time points during the study, with main outcomes being change from pre-intervention to post-intervention.
Interventions
A 14-module stress management and lifestyle group-based intervention delivered via videoconferencing WebEx technology to participants who have/had chronic hepatitis C and experience symptoms, stress or lifestyle requirements to promote liver health.
Sponsors
Study design
Intervention model description
Participants (n=32) were assigned by 3:1 randomization to VC-CBCS or SC. Participants were recruited in 4 cohorts (Wave 1: n=7, Wave 2: n=9, Waves 3, 4: n=8 each). In Wave 1, 5 participants were randomized to VC-CBCS and 2 to SC. In Wave 2, 7 participants were randomized to VC-CBCS and 2 to SC. In Waves 3 and 4, 6 participants were randomized to VC-CBCS and 2 to SC.
Eligibility
Inclusion criteria
* Age 21 and older; * Medically cleared by hepatology * Patients who are currently or were previously diagnosed with chronic Hepatitis C Viral (HCV) infection; * Evidence of ongoing symptoms, stress, or unhealthy lifestyle habits, defined as a score of greater than or equal to 4 on a scale 0(none) - 10 (severe) on two or more numeric rating scale questions (see Screening Form 1); * Able to read and speak English.
Exclusion criteria
* Decompensated liver disease (Childs Pugh C) judged by hepatologist or recorded in patient medical record; * Life expectancy of \<12 months estimated by hepatologist; * Has had a liver transplant or is on the wait list for a transplant * Severe alcohol or substance use disorder, psychiatric disorder or cognitive impairment that is likely to interfere with the ability to participate in telehealth groups and follow guidelines about group participation as judged by the Hepatology provider or research staff; * Lack of private, quiet space in home in which to participate in VC-CBCS sessions * Unwilling to have intervention sessions audio-recorded
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain Interference Mean T-score | Baseline (T1), Week 14 (T4) | The PROMIS Pain Interference measure is an 8-item short form that was used to measure patient-reported pain interference. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 41.6 to 75.6. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Pain Interference and T-score=40 is 1 standard deviation less Pain Interference than the general population. |
| Sleep Disturbance Mean T-score | Baseline (T1), Week 14 (T4) | The PROMIS Sleep Disturbance measure is an 8-item short form that was used to measure patient-reported sleep disturbance. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 32.0 to 73.3. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Sleep Disturbance and T-score=40 is 1 standard deviation less Sleep Disturbance than the general population. |
| Percentage of VC-CBCS Intervention Condition Participants Retained vs Enrolled | Six Months | Percentage of VC-CBCS Intervention participants retained in the study compared to those enrolled. Retention is defined as participants who completed at least 3 intervention sessions. |
| Percentage of Surveys Completed by Participants Who Completed the Study | Baseline (T1) to Week 14 (T4) | Percentage of surveys over time completed by participants who completed the study. Surveys included 12 patient-reported primary and secondary outcome measures. Completion was defined as submission of each of the 12 surveys at Time 1 (T1) through Time 4 (T4). |
| Percentage of Patients Consented Versus Approached | Six Months | One feasibility measure was to evaluate the percentage of patients consented compared to those approached for participation in the study. |
| Percentage of Participants Consented Versus Randomized | Six Months | One feasibility measure was to evaluate the percentage of participants randomized for the study compared to those consented. |
| Percentage of Standard of Care Condition Participants Retained vs Enrolled | Six Months | Percentage of standard of care condition participants retained in the study compared to those enrolled. Retention is defined as participants who submitted PRO assessments up through T4 (end of study). |
| Global Health Status Physical Health Mean T-Score | Baseline (T1), Week 14 (T4) | The Patient Reported Outcome Measurement Information System (PROMIS) Global Health Status measure is a 10-item short form that was used to measure an individual's physical, mental, and social health. Item responses range from 5 = None to 1 = Very Severe. The adult PROMIS Global Health measure produces two scores: Physical Health and Mental Health. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 16.2 to 67.7. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation better (more healthy) than the general population. |
| Global Health Status Mental Health Mean T-Score | Baseline (T1), Week 14 (T4) | The PROMIS Global Health Status measure is a 10-item short form that was used to measure an individual's physical, mental, and social health. Item responses range from 5 = None to 1 = Very Severe. The adult PROMIS Global Health measure produces two scores: Physical Health and Mental Health. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 21.2 to 67.7. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation better (more healthy) than the general population. |
| Depression Mean T-score | Baseline (T1), Week 14 (T4) | The PROMIS Depression measure is an 8-item short form that was used to measure patient-reported depression. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 41.0 to 79.4. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more (more Depression) than the general population. |
| Anger Mean T-score | Baseline (T1), Week 14 (T4) | The PROMIS Anger measure is a 5-item short form that was used to measure patient-reported anger. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 32.9 to 82.9. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Anger and T-score=40 is 1 standard deviation less Anger than the general population. |
| Anxiety Mean T-score | Baseline (T1), Week 14 (T4) | The PROMIS Anxiety measure is a 4-item short form that was used to measure patient-reported anxiety. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 40.3 to 81.6. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Anxiety and T-score=40 is 1 standard deviation less Anxiety than the general population. The Anxiety T-score can range from 40.3 - 81.6. |
| Fatigue Mean T-score | Baseline (T1), Week 14 (T4) | The PROMIS Fatigue measure is a 7-item short form that was used to measure patient-reported fatigue. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 29.4 to 83.2. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Fatigue and T-score=40 is 1 standard deviation less Fatigue than the general population. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Who Complete Moderate Activity for at Least 10 Minutes at a Time | Baseline (T1), Week 14 (T4) | Behavioral Risk Factor Surveillance System (BRFSS) items measured moderate activity as a health behavior in all participants at T1 (baseline) and T4 (week 14) and will cover 30 days prior to assessment. BRFSS item asks Do you do moderate activity for at least 10 minutes at a time? Response options: Yes/No. Percentage is participants who indicate Yes to doing moderate activity for at least 10 minutes at a time |
| Mean Number of Minutes of Moderate Activity Per Week | Baseline (T1) , Week 14 (T4) | Behavioral Risk Factor Surveillance System (BRFSS) items measured moderate activity as a health behavior by combining two BRFSS items: If yes, how many days per week do you do these moderate activities for at least 10 minutes at a time and If yes, how much total time per day do you spend doing these activities? Total number of minutes of moderate activity per week calculated as number of days x number of minutes. |
| Percentage of Participants Who Complete Vigorous Activity for at Least 10 Minutes at a Time | Baseline (T1), Week 14 (T4) | Behavioral Risk Factor Surveillance System (BRFSS) items measured vigorous activity as a health behavior - BRFSS Item Do you do vigorous activity for at least 10 minutes at a time? Response option: Yes/No. Percentage is participants who indicate Yes to doing vigorous activity for at least 10 minutes at a time |
| Mean Number of Minutes of Vigorous Activity Per Week | Baseline (T1), Week 14 (T4) | Behavioral Risk Factor Surveillance System (BRFSS) items measured vigorous activity as a health behavior by combining two BRFSS items: If yes, How many days per week do you do these vigorous activities for at least 10 minutes at a time and If yes, how much total time per day do you spend doing these activities? Total number of minutes of vigorous activity per week calculated as number of days x number of minutes. |
| Mean Time Spent Sitting on the Weekdays | Baseline (T1), Week 14 (T4) | Behavioral Risk Factor Surveillance System (BRFSS) items measured sedentarism as a health behavior - BRFSS item What is the total number of hours you spend siting on a weekday? The mean can range from a minimum of 0 to maximum of 24 hours. Average numbers of hours spent sitting on the weekday was assessed at T1 to T4. |
| Mean Time Spent Sitting on the Weekends | Baseline (T1), Week 14 (T4) | Behavioral Risk Factor Surveillance System (BRFSS) items measured sedentarism as a health behavior - BRFSS Item What is the total number of hours you spend sitting on a weekend day? Mean ranges from a minimum of 0 to maximum of 24 hours. Average numbers of hours spent sitting on the weekends assessed at T1 and T4. |
| Percentage of Participants Who Reduced Regular Soda Intake by One or More Categories | Baseline (T1) to Week 14 (T4) | Behavioral Risk Factor Surveillance System (BRFSS) items measured soda intake as a health behavior - BRFSS item During the past 30 days, how often did you drink regular soda or pop that contains sugar? Do not include diet soda or diet pop. Original 9-point response scale ranged from Never to 6 more more per day. Recoded 9 categories into 5 categories, ranging from Never to Daily. The percentage is the number of participants who improved (consumed less) by 1 or more categories on the 5 category levels from T1 to T4. |
| Percentage of Participants Who Reduced Diet Soda Intake by One or More Categories | Baseline (T1) to Week 14 (T4) | Behavioral Risk Factor Surveillance System (BRFSS) items measured diet soda intake as a health behavior - BRFSS item During the past 30 days, how often did you drink diet soda or diet pop that contains an artificial sweeter? Original 9-point response scale ranged from Never to 6 or more per day. Recoded 9 categories into 5, ranging from Never to Daily. The percentage is the number of patients who improved (consumed less) by 1 or more categories on the 5 recoded category level from T1 to T4. |
| Percentage of Participants Who Reduced Fruit Juice Intake by One or More Categories | Baseline (T1) to Week 14 (T4) | Behavioral Risk Factor Surveillance System (BRFSS) items measured fruit juice intake as a health behavior - BRFSS item During the past month, how many times per day, week or month did you drink 100% pure fruit juices? Original 9-point response scale ranged from Never to 6 or more per day. Recoded 9 categories into 5, ranging from Never to Daily. The percentage is the number of participants who improved (consumed less) by 1 or more categories on the 5 recoded category levels from T1 to T4. |
| Percentage of Participants Who Reduced Meals From Fast Food Restaurants by One or More Categories | Baseline (T1) to Week 14 (T4) | Behavioral Risk Factor Surveillance System (BRFSS) items measured fast food intake as a health behavior - BRFSS item In a typical week, how many of your own meals come from fast food restaurants? Original 9-point response scale ranged from Never to 6 or more per day. Recoded 9 categories into 5, ranging from Never to Daily. The percentage is the number of participants who improved (reduced) by 1 or more categories on the 5 recoded category levels from T1 to T4. |
| Percentage of Participants Who Increased Dinners Prepared at Home by 1 or More Days | Baseline (T1) to Week 14 (T4) | Behavioral Risk Factor Surveillance System (BRFSS) items measured food prepared at home as a health behavior - BRFSS item On how many days per week do you usually eat a dinner that is prepared at home? 7-point response scale ranged from 0 to 7 days. The percentage is the number of patients who improved (increased) by 1 or more days from T1 to T4. |
| Change in Weight (Lbs) | Baseline (T1) to Week 14 (T4) | Change in weight (lbs) among those who had pre-intervention BMI \> 24.9 (obese and above) from T1 to T4. |
| Change in Percent Weight Change | Baseline (T1) to Week 14 (T4) | Change in percent weight (lbs) among those who had pre-intervention BMI \> 24.9 (obese and above) from T1 to T4. |
| Prescription Drug Misuse Total Mean Score | Baseline (T1), Week 14 (T4) | Surveys administered at baseline (T1) and Week 14 (T4) evaluated self-reported prescription drug misuse in all participants. One item from the Substance Abuse and Mental Illness Symptoms Screener (SAMISS) Survey evaluated misuse of prescription drugs in the last year. The response options ranged from a minimum of 0=Never to a maximum of 4=Daily/Almost Daily. Higher scores indicate higher consumption. |
| Non-prescription Street Drug Use Total Mean Score | Baseline (T1), Week 14 (T4) | Surveys administered at baseline (T1) and Week 14 (T4) evaluated self-reported non-prescription street drug use in all participants. One item from the Substance Abuse and Mental Illness Symptoms Screener (SAMISS) Survey evaluated non-prescription street drug use in the last year. The response options ranged from a minimum of 0=Never to a maximum of 4=Daily/Almost Daily. Higher scores indicate higher consumption. |
| Pittsburgh Sleep Quality Index (PSQI) Sleep Efficiency Composite Mean Score | Baseline (T1), Week 14 (T4) | Items 1, 3 and 4 from the Pittsburgh Sleep Quality Index (PSQI) were used to create a Sleep Efficiency composite score. All participants completed this measure at T1 and T4 that covered 30 days prior to assessment. The sleep efficiency score = (# hours slept/# hours in bed) X 100% .The sleep efficiency composite score ranged from: 0 = \>85% efficiency, 1 = 75-84% efficiency, 2= 65-74% efficiency, and 3= \<65%. Lower scores indicate better sleep efficiency. |
| Healthy Sleep Behaviors Mean Score | Baseline (T1), Week 14 (T4) | One item In the last month, how often did you engage in healthy sleep behaviors before bedtime? evaluated healthy sleep behaviors. All participants completed this measure at T1 and T4. The response set ranged from 0 (not at all) to 4 (almost every night). Higher scores indicated better sleep behaviors. |
| Change in Body Mass Index (BMI) | Baseline (T1) to Week 14 (T4) | Change in Body Mass Index (BMI) among those who had pre-intervention BMI \> 24.9 (obese and above) from T1 to T4. |
| Perceived Stress Mean Score | Baseline (T1), Week 14 (T4) | The Perceived Stress Scale (PSS) is a widely used survey to measure stress perception. The scale includes 10 items, rated using a 5-point scale, from 0 (never) to 4 (very often) where patients report the frequency of stress symptoms in the past month. Items are summed with a minimum and maximum ranging from 0 to 40. Higher PSS scores reflect higher subjective stress. |
| Coping Skills Confidence Mean Score | Baseline (T1), Week 14 (T4) | The Measure of Current Status (MOCS)-Part A measured participant confidence in performing multiple skills including stress awareness, relaxation, assertiveness, and coping skills. The scale contains 13 items rated on a scale from 0 = I cannot do this at all to 4 = I can do this extremely well. A Total Coping Skills score is created by taking the average of the 13 items. The Total Coping Skill score can range from a minimum of 0 to a maximum of 4. |
| Participant Satisfaction With VC-CBCS Intervention Mean Score | Baseline (T1) to Week 14 (T4) | After each VC-CBCS intervention session, participants completed a 14-item acceptability/satisfaction survey about their impressions with the current intervention session. Items are scored on a scale from 1= not at all to 5=extremely useful. Data across all VC-CBCS participants and all intervention sessions were averaged into a Total Patient Satisfaction score that could range from a minimum of 1 to a maximum of 5 with higher scores indicating greater satisfaction. |
| Aspartate Aminotransferase (AST) Mean Score for Females | Baseline (T1), Week 14 (T4) | Liver enzyme level (AST U/L). Reference range for females is 14-38 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on medical treatment for chronic hepatitis C at baseline. |
| Aspartate Aminotransferase (AST) Mean Score for Males | Baseline (T1), Week 14 (T4) | Liver enzyme level (AST U/L). Reference range for males is 19-55 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on Hepatitis C Virus (HCV) treatment at baseline. |
| Alanine Aminotransferase (ALT) Mean Score for Females | Baseline (T1), Week 14 (T4) | Liver enzyme level (ALT U/L). Reference range for females is \<35 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on HCV treatment at baseline. |
| Alanine Aminotransferase (ALT) Mean Score for Males | Baseline (T1), Week 14 (T4) | Liver enzyme level (ALT U/L). Reference range for males is \<50 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on HCV treatment at baseline. |
| Pittsburgh Sleep Quality Index (PSQI) Sleep Quality Mean Score | Baseline (T1), Week 14 (T4) | Item 9 from the Pittsburgh Sleep Quality Index (PSQI) was used to measure sleep quality. All participants completed this measure at PRO time points T1 and T4 that covered 30 days prior to assessment. During the past month, how would you rate your sleep quality overall? The response set ranged from a minimum of 0 (Very Good) to a maximum of 3 (Very Bad). Higher scores indicated worse sleep quality. |
| Percentage of Overall Medication Adherence | Baseline (T1), Week 14 (T4) | Medication Adherence Visual Analog Scales (VAS) was used to evaluate medication adherence for up to five daily medications for multiple comorbidities in the past 7 days in participants who were prescribed medications at baseline. Participants reported the average adherence over the course of 7 days for each medication on a scale from 0% to 100% adherence for each medication. The average percent adherence was created for all medications for each patient and could range from 0% to 100%. Overall medication adherence adherence was assessed at T1 and T4. |
| Alcohol Total Mean Score | Baseline (T1), Week 14 (T4) | Three items from the Substance Abuse and Mental Illness Symptoms Screener (SAMISS) Survey was administered at baseline (T1) and Week 14 (T4) to evaluate self-reported alcohol use in all participants. The three items evaluated frequency, amount of alcohol consumption, and binge drinking. Individual scores could range from 0 to 4, with higher scores indicating higher consumption. |
| Percentage of Participants Who Improved Fruit Consumption by One or More Categories | Baseline (T1) to Week 14 (T4) | Behavioral Risk Factor Surveillance System (BRFSS) items assessed fruit intake as a health behavior - Over the past 12 months, how often did you eat fruits? Original 8-point response scale ranged from 1 time per month to 2 or more times/day. Recoded 8 categories into 4 categories, ranging from Daily consumption to Less than weekly. The percentage shown is the number of participants who improved by 1 or more categories based on the 4 category levels from T1 to T4. |
| Percentage of Participants Who Improved Vegetable Consumption by One or More Categories | Baseline (T1) to Week 14 (T4) | Behavioral Risk Factor Surveillance System (BRFSS) items measured vegetable intake as a health behavior - Over the past 12 months, how often did you eat vegetables? Original 8-point response scale ranged from 1 time per month to 2 or more times/day. Recoded 8 categories into 4 categories, ranging from Daily consumption to Less than weekly. The percentage is the number of participants who improved by 1 or more categories on the 4 category levels from T1 to T4. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Salivary Cortisol Area Under the Curve With Respect to Ground (AUC-G) | Baseline (T1), Week 14 (T4) | Participants in both conditions collected saliva samples at Baseline (T1) and Week 14 (T4). Participants were instructed to collect four saliva samples at each timepoint; 1) immediately upon awakening 2) 30 minutes after awakening 3) late afternoon 4) before bedtime. The mean AUC-G was then obtained at T1 and T4. Mean AUC-G scores could range from 0.195 to 2.29. |
| Participant Satisfaction With VC-CBCS Telehealth Session Mean Score | Baseline (T1) to Week 14 (T4) | After intervention week 1 and week 14, participants in the VC-CBCS intervention completed a 15-item acceptability/satisfaction survey about their satisfaction with using telehealth sessions. Items were scored on a scale from 1= strongly disagree to 5=strongly agree. The average Total Telehealth Satisfaction score from week 1 and week 14 was created, which ranged from 1 to 5 with higher scores indicating greater satisfaction. A previously developed Telehealth Patient Satisfaction Questionnaire was modified for this study. |
Countries
United States
Participant flow
Pre-assignment details
53 participants were approached for study interest; 39 were consented and of those 32 were enrolled.
Participants by arm
| Arm | Count |
|---|---|
| VC-CBCS Intervention The VC-CBCS intervention was delivered via WebEx videoconferencing technology and included 14, 2-hour long sessions that included group-based psychoeducation, cognitive and behavioral skills training, stress management, relaxation practice and healthy lifestyle habits to support overall health and liver health. Intervention materials included a hard copy patient Workbook and audio-recorded relaxation techniques. | 24 |
| Standard of Care (SC) Participants randomized to SC received no intervention and were followed by medical providers in clinic per clinical practice guidelines and clinicians discretion. | 8 |
| Total | 32 |
Baseline characteristics
| Characteristic | VC-CBCS Intervention | Total | Standard of Care (SC) |
|---|---|---|---|
| Age, Continuous | 56 years STANDARD_DEVIATION 7.5 | 56 years STANDARD_DEVIATION 8.5 | 56 years STANDARD_DEVIATION 11.4 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 14 Participants | 19 Participants | 5 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 10 Participants | 13 Participants | 3 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 2 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 5 Participants | 7 Participants | 2 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 16 Participants | 21 Participants | 5 Participants |
| Region of Enrollment United States | 24 Participants | 32 Participants | 8 Participants |
| Sex: Female, Male Female | 5 Participants | 8 Participants | 3 Participants |
| Sex: Female, Male Male | 19 Participants | 24 Participants | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 21 | 0 / 8 |
| other Total, other adverse events | 0 / 21 | 0 / 8 |
| serious Total, serious adverse events | 1 / 21 | 0 / 8 |
Outcome results
Anger Mean T-score
The PROMIS Anger measure is a 5-item short form that was used to measure patient-reported anger. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 32.9 to 82.9. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Anger and T-score=40 is 1 standard deviation less Anger than the general population.
Time frame: Baseline (T1), Week 14 (T4)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| All Patients | Anger Mean T-score | Baseline (T1) | 51.0 T-score |
| All Patients | Anger Mean T-score | Week 14 (T4) | 46.5 T-score |
| Standard of Care (SC) | Anger Mean T-score | Baseline (T1) | 52.3 T-score |
| Standard of Care (SC) | Anger Mean T-score | Week 14 (T4) | 46.9 T-score |
Anxiety Mean T-score
The PROMIS Anxiety measure is a 4-item short form that was used to measure patient-reported anxiety. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 40.3 to 81.6. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Anxiety and T-score=40 is 1 standard deviation less Anxiety than the general population. The Anxiety T-score can range from 40.3 - 81.6.
Time frame: Baseline (T1), Week 14 (T4)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| All Patients | Anxiety Mean T-score | Baseline (T1) | 52.7 T-score |
| All Patients | Anxiety Mean T-score | Week 14 (T4) | 50.4 T-score |
| Standard of Care (SC) | Anxiety Mean T-score | Baseline (T1) | 57.7 T-score |
| Standard of Care (SC) | Anxiety Mean T-score | Week 14 (T4) | 51.2 T-score |
Depression Mean T-score
The PROMIS Depression measure is an 8-item short form that was used to measure patient-reported depression. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 41.0 to 79.4. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more (more Depression) than the general population.
Time frame: Baseline (T1), Week 14 (T4)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| All Patients | Depression Mean T-score | Baseline (T1) | 52.3 T-score |
| All Patients | Depression Mean T-score | Week 14 (T4) | 48.6 T-score |
| Standard of Care (SC) | Depression Mean T-score | Baseline (T1) | 51.6 T-score |
| Standard of Care (SC) | Depression Mean T-score | Week 14 (T4) | 49.0 T-score |
Fatigue Mean T-score
The PROMIS Fatigue measure is a 7-item short form that was used to measure patient-reported fatigue. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 29.4 to 83.2. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Fatigue and T-score=40 is 1 standard deviation less Fatigue than the general population.
Time frame: Baseline (T1), Week 14 (T4)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| All Patients | Fatigue Mean T-score | Baseline (T1) | 51.9 T-score |
| All Patients | Fatigue Mean T-score | Week 14 (T4) | 48.6 T-score |
| Standard of Care (SC) | Fatigue Mean T-score | Baseline (T1) | 50.4 T-score |
| Standard of Care (SC) | Fatigue Mean T-score | Week 14 (T4) | 46.6 T-score |
Global Health Status Mental Health Mean T-Score
The PROMIS Global Health Status measure is a 10-item short form that was used to measure an individual's physical, mental, and social health. Item responses range from 5 = None to 1 = Very Severe. The adult PROMIS Global Health measure produces two scores: Physical Health and Mental Health. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 21.2 to 67.7. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation better (more healthy) than the general population.
Time frame: Baseline (T1), Week 14 (T4)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| All Patients | Global Health Status Mental Health Mean T-Score | Baseline (T1) | 46.7 T-score |
| All Patients | Global Health Status Mental Health Mean T-Score | Week 14 (T4) | 49.3 T-score |
| Standard of Care (SC) | Global Health Status Mental Health Mean T-Score | Baseline (T1) | 41.9 T-score |
| Standard of Care (SC) | Global Health Status Mental Health Mean T-Score | Week 14 (T4) | 45.9 T-score |
Global Health Status Physical Health Mean T-Score
The Patient Reported Outcome Measurement Information System (PROMIS) Global Health Status measure is a 10-item short form that was used to measure an individual's physical, mental, and social health. Item responses range from 5 = None to 1 = Very Severe. The adult PROMIS Global Health measure produces two scores: Physical Health and Mental Health. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 16.2 to 67.7. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation better (more healthy) than the general population.
Time frame: Baseline (T1), Week 14 (T4)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| All Patients | Global Health Status Physical Health Mean T-Score | Baseline (T1) | 45.7 T-score |
| All Patients | Global Health Status Physical Health Mean T-Score | Week 14 (T4) | 46.0 T-score |
| Standard of Care (SC) | Global Health Status Physical Health Mean T-Score | Baseline (T1) | 41.8 T-score |
| Standard of Care (SC) | Global Health Status Physical Health Mean T-Score | Week 14 (T4) | 48 T-score |
Pain Interference Mean T-score
The PROMIS Pain Interference measure is an 8-item short form that was used to measure patient-reported pain interference. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 41.6 to 75.6. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Pain Interference and T-score=40 is 1 standard deviation less Pain Interference than the general population.
Time frame: Baseline (T1), Week 14 (T4)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| All Patients | Pain Interference Mean T-score | Baseline (T1) | 53.5 T-score |
| All Patients | Pain Interference Mean T-score | Week 14 (T4) | 52.0 T-score |
| Standard of Care (SC) | Pain Interference Mean T-score | Baseline (T1) | 55.8 T-score |
| Standard of Care (SC) | Pain Interference Mean T-score | Week 14 (T4) | 54.6 T-score |
Percentage of Participants Consented Versus Randomized
One feasibility measure was to evaluate the percentage of participants randomized for the study compared to those consented.
Time frame: Six Months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Patients | Percentage of Participants Consented Versus Randomized | 82 percentage of participants |
Percentage of Patients Consented Versus Approached
One feasibility measure was to evaluate the percentage of patients consented compared to those approached for participation in the study.
Time frame: Six Months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Patients | Percentage of Patients Consented Versus Approached | 74 percentage of participants |
Percentage of Standard of Care Condition Participants Retained vs Enrolled
Percentage of standard of care condition participants retained in the study compared to those enrolled. Retention is defined as participants who submitted PRO assessments up through T4 (end of study).
Time frame: Six Months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Patients | Percentage of Standard of Care Condition Participants Retained vs Enrolled | 100 percentage of participants |
Percentage of Surveys Completed by Participants Who Completed the Study
Percentage of surveys over time completed by participants who completed the study. Surveys included 12 patient-reported primary and secondary outcome measures. Completion was defined as submission of each of the 12 surveys at Time 1 (T1) through Time 4 (T4).
Time frame: Baseline (T1) to Week 14 (T4)
Population: Data collection rate is for those who completed the study - 8 Standard of Care and 19 VC-CBCS, total of 27 participants.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Patients | Percentage of Surveys Completed by Participants Who Completed the Study | 99.4 percentage of surveys completed |
Percentage of VC-CBCS Intervention Condition Participants Retained vs Enrolled
Percentage of VC-CBCS Intervention participants retained in the study compared to those enrolled. Retention is defined as participants who completed at least 3 intervention sessions.
Time frame: Six Months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Patients | Percentage of VC-CBCS Intervention Condition Participants Retained vs Enrolled | 79.2 percentage of participants |
Sleep Disturbance Mean T-score
The PROMIS Sleep Disturbance measure is an 8-item short form that was used to measure patient-reported sleep disturbance. Item responses range from 1 = Never to 5 = Always. The raw scores are converted into a T-score. T-Score distributions are standardized such that a 50 represents the average (mean) for the US general population, and the standard deviation around that mean is 10 points. The minimum and maximum T-scores ranged from 32.0 to 73.3. Higher T- scores indicate more of that construct, for example, a T-score=60 is 1 standard deviation more Sleep Disturbance and T-score=40 is 1 standard deviation less Sleep Disturbance than the general population.
Time frame: Baseline (T1), Week 14 (T4)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| All Patients | Sleep Disturbance Mean T-score | Baseline (T1) | 52.0 T-score |
| All Patients | Sleep Disturbance Mean T-score | Week 14 (T4) | 50.0 T-score |
| Standard of Care (SC) | Sleep Disturbance Mean T-score | Baseline (T1) | 50.8 T-score |
| Standard of Care (SC) | Sleep Disturbance Mean T-score | Week 14 (T4) | 46.0 T-score |
Alanine Aminotransferase (ALT) Mean Score for Females
Liver enzyme level (ALT U/L). Reference range for females is \<35 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on HCV treatment at baseline.
Time frame: Baseline (T1), Week 14 (T4)
Population: The analytic sample includes 4 females who completed the VC-CBCS intervention and 3 females in Standard of Care. Of these, 1 VC-CBCS Intervention participant had missing data at T4. Of the 3 females in Standard of Care, 2 had missing data at T1 and all 3 participants had missing data at T4.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Patients | Alanine Aminotransferase (ALT) Mean Score for Females | Baseline (T1) | 22.0 U/L | Standard Deviation 13 |
| All Patients | Alanine Aminotransferase (ALT) Mean Score for Females | Week 14 (T4) | 28.3 U/L | Standard Deviation 20 |
| Standard of Care (SC) | Alanine Aminotransferase (ALT) Mean Score for Females | Baseline (T1) | 13.0 U/L | Standard Deviation 0 |
Alanine Aminotransferase (ALT) Mean Score for Males
Liver enzyme level (ALT U/L). Reference range for males is \<50 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on HCV treatment at baseline.
Time frame: Baseline (T1), Week 14 (T4)
Population: The analytic sample includes 14 males who completed the VC-CBCS intervention and 5 males in Standard of Care. Of these, 4 VC-CBCS Intervention participants had missing data at T1 and 5 at T4. Of the 5 males in Standard of Care, 1 had missing data at T1 and 2 had missing data at T4.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Patients | Alanine Aminotransferase (ALT) Mean Score for Males | Baseline (T1) | 34.6 U/L | Standard Deviation 23 |
| All Patients | Alanine Aminotransferase (ALT) Mean Score for Males | Week 14 (T4) | 36.9 U/L | Standard Deviation 24.1 |
| Standard of Care (SC) | Alanine Aminotransferase (ALT) Mean Score for Males | Baseline (T1) | 33.0 U/L | Standard Deviation 10.3 |
| Standard of Care (SC) | Alanine Aminotransferase (ALT) Mean Score for Males | Week 14 (T4) | 28.0 U/L | Standard Deviation 12.5 |
Alcohol Total Mean Score
Three items from the Substance Abuse and Mental Illness Symptoms Screener (SAMISS) Survey was administered at baseline (T1) and Week 14 (T4) to evaluate self-reported alcohol use in all participants. The three items evaluated frequency, amount of alcohol consumption, and binge drinking. Individual scores could range from 0 to 4, with higher scores indicating higher consumption.
Time frame: Baseline (T1), Week 14 (T4)
Population: 1 VC-CBCS Intervention participant with missing data at T1.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Patients | Alcohol Total Mean Score | Baseline (T1) | 1.39 score on a scale | Standard Deviation 2.43 |
| All Patients | Alcohol Total Mean Score | Week 14 (T4) | 0.95 score on a scale | Standard Deviation 2.27 |
| Standard of Care (SC) | Alcohol Total Mean Score | Baseline (T1) | 0.13 score on a scale | Standard Deviation 0.35 |
| Standard of Care (SC) | Alcohol Total Mean Score | Week 14 (T4) | 0.25 score on a scale | Standard Deviation 0.71 |
Aspartate Aminotransferase (AST) Mean Score for Females
Liver enzyme level (AST U/L). Reference range for females is 14-38 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on medical treatment for chronic hepatitis C at baseline.
Time frame: Baseline (T1), Week 14 (T4)
Population: The analytic sample includes 4 females who completed the VC-CBCS intervention and 3 females in Standard of Care. Of these, 1 VC-CBCS Intervention participant had missing data at T4. Of the 3 females in Standard of Care, 2 had missing data at T1 and all 3 participants had missing data at T4.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Patients | Aspartate Aminotransferase (AST) Mean Score for Females | Baseline (T1) | 28.0 U/L | Standard Deviation 8.91 |
| All Patients | Aspartate Aminotransferase (AST) Mean Score for Females | Week 14 (T4) | 31.0 U/L | Standard Deviation 8.89 |
| Standard of Care (SC) | Aspartate Aminotransferase (AST) Mean Score for Females | Baseline (T1) | 23.0 U/L | Standard Deviation 0 |
Aspartate Aminotransferase (AST) Mean Score for Males
Liver enzyme level (AST U/L). Reference range for males is 19-55 U/L. Numbers higher than these reference ranges are considered in the abnormal range and can suggest liver damage or inflammation. These comparisons were only made for participants who had already achieved viral cure at baseline and who were not on Hepatitis C Virus (HCV) treatment at baseline.
Time frame: Baseline (T1), Week 14 (T4)
Population: The analytic sample includes 14 males who completed the VC-CBCS intervention and 5 males in Standard of Care. Of these, 4 VC-CBCS Intervention participants had missing data at T1 and 5 at T4. Of the 5 males in Standard of Care, 1 had missing data at T1 and 2 had missing data at T4.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Patients | Aspartate Aminotransferase (AST) Mean Score for Males | Baseline (T1) | 34.7 U/L | Standard Deviation 11.2 |
| All Patients | Aspartate Aminotransferase (AST) Mean Score for Males | Week 14 (T4) | 30.0 U/L | Standard Deviation 8.39 |
| Standard of Care (SC) | Aspartate Aminotransferase (AST) Mean Score for Males | Baseline (T1) | 36.5 U/L | Standard Deviation 17.3 |
| Standard of Care (SC) | Aspartate Aminotransferase (AST) Mean Score for Males | Week 14 (T4) | 45.3 U/L | Standard Deviation 31.8 |
Change in Body Mass Index (BMI)
Change in Body Mass Index (BMI) among those who had pre-intervention BMI \> 24.9 (obese and above) from T1 to T4.
Time frame: Baseline (T1) to Week 14 (T4)
Population: 8 participants had missing data for this variable (4 VC-CBCS Intervention, 4 Standard of Care)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| All Patients | Change in Body Mass Index (BMI) | -0.53 kg/m^2 | Standard Deviation 2.28 |
| Standard of Care (SC) | Change in Body Mass Index (BMI) | 0.23 kg/m^2 | Standard Deviation 0.83 |
Change in Percent Weight Change
Change in percent weight (lbs) among those who had pre-intervention BMI \> 24.9 (obese and above) from T1 to T4.
Time frame: Baseline (T1) to Week 14 (T4)
Population: 8 participants had missing data for this variable (4 VC-CBCS Intervention, 4 Standard of Care)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| All Patients | Change in Percent Weight Change | 0.91 percent of weight change | Standard Deviation 5.65 |
| Standard of Care (SC) | Change in Percent Weight Change | -0.23 percent of weight change | Standard Deviation 1.91 |
Change in Weight (Lbs)
Change in weight (lbs) among those who had pre-intervention BMI \> 24.9 (obese and above) from T1 to T4.
Time frame: Baseline (T1) to Week 14 (T4)
Population: 8 participants had missing data for this variable (4 VC-CBCS Intervention, 4 Standard of Care)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| All Patients | Change in Weight (Lbs) | -2.67 pounds | Standard Deviation 13.7 |
| Standard of Care (SC) | Change in Weight (Lbs) | 0.0 pounds | Standard Deviation 3.56 |
Coping Skills Confidence Mean Score
The Measure of Current Status (MOCS)-Part A measured participant confidence in performing multiple skills including stress awareness, relaxation, assertiveness, and coping skills. The scale contains 13 items rated on a scale from 0 = I cannot do this at all to 4 = I can do this extremely well. A Total Coping Skills score is created by taking the average of the 13 items. The Total Coping Skill score can range from a minimum of 0 to a maximum of 4.
Time frame: Baseline (T1), Week 14 (T4)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| All Patients | Coping Skills Confidence Mean Score | Baseline (T1) | 2.18 score on a scale |
| All Patients | Coping Skills Confidence Mean Score | Week 14 (T4) | 2.74 score on a scale |
| Standard of Care (SC) | Coping Skills Confidence Mean Score | Baseline (T1) | 2.16 score on a scale |
| Standard of Care (SC) | Coping Skills Confidence Mean Score | Week 14 (T4) | 2.38 score on a scale |
Healthy Sleep Behaviors Mean Score
One item In the last month, how often did you engage in healthy sleep behaviors before bedtime? evaluated healthy sleep behaviors. All participants completed this measure at T1 and T4. The response set ranged from 0 (not at all) to 4 (almost every night). Higher scores indicated better sleep behaviors.
Time frame: Baseline (T1), Week 14 (T4)
Population: 2 Standard of Care participants were missing data for this variable at T4
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Patients | Healthy Sleep Behaviors Mean Score | Week 14 (T4) | 2.42 score on a scale | Standard Deviation 0.84 |
| All Patients | Healthy Sleep Behaviors Mean Score | Baseline (T1) | 1.37 score on a scale | Standard Deviation 1.26 |
| Standard of Care (SC) | Healthy Sleep Behaviors Mean Score | Baseline (T1) | 2.13 score on a scale | Standard Deviation 0.99 |
| Standard of Care (SC) | Healthy Sleep Behaviors Mean Score | Week 14 (T4) | 2.17 score on a scale | Standard Deviation 1.33 |
Mean Number of Minutes of Moderate Activity Per Week
Behavioral Risk Factor Surveillance System (BRFSS) items measured moderate activity as a health behavior by combining two BRFSS items: If yes, how many days per week do you do these moderate activities for at least 10 minutes at a time and If yes, how much total time per day do you spend doing these activities? Total number of minutes of moderate activity per week calculated as number of days x number of minutes.
Time frame: Baseline (T1) , Week 14 (T4)
Population: 5 participants with missing data for this variable (4 VC-CBCS intervention participants, 1 Standard of Care)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Patients | Mean Number of Minutes of Moderate Activity Per Week | Baseline (T1) | 314 minutes | Standard Deviation 556 |
| All Patients | Mean Number of Minutes of Moderate Activity Per Week | Week 14 (T4) | 528 minutes | Standard Deviation 808 |
| Standard of Care (SC) | Mean Number of Minutes of Moderate Activity Per Week | Baseline (T1) | 87.9 minutes | Standard Deviation 120 |
| Standard of Care (SC) | Mean Number of Minutes of Moderate Activity Per Week | Week 14 (T4) | 170 minutes | Standard Deviation 257 |
Mean Number of Minutes of Vigorous Activity Per Week
Behavioral Risk Factor Surveillance System (BRFSS) items measured vigorous activity as a health behavior by combining two BRFSS items: If yes, How many days per week do you do these vigorous activities for at least 10 minutes at a time and If yes, how much total time per day do you spend doing these activities? Total number of minutes of vigorous activity per week calculated as number of days x number of minutes.
Time frame: Baseline (T1), Week 14 (T4)
Population: 2 participants missing data for this variable (1 VC-CBCS Intervention, 1 Standard of Care)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Patients | Mean Number of Minutes of Vigorous Activity Per Week | Baseline (T1) | 241 total minutes in a week | Standard Deviation 457 |
| All Patients | Mean Number of Minutes of Vigorous Activity Per Week | Week 14 (T4) | 235 total minutes in a week | Standard Deviation 513 |
| Standard of Care (SC) | Mean Number of Minutes of Vigorous Activity Per Week | Baseline (T1) | 55.7 total minutes in a week | Standard Deviation 74.4 |
| Standard of Care (SC) | Mean Number of Minutes of Vigorous Activity Per Week | Week 14 (T4) | 17.1 total minutes in a week | Standard Deviation 34 |
Mean Time Spent Sitting on the Weekdays
Behavioral Risk Factor Surveillance System (BRFSS) items measured sedentarism as a health behavior - BRFSS item What is the total number of hours you spend siting on a weekday? The mean can range from a minimum of 0 to maximum of 24 hours. Average numbers of hours spent sitting on the weekday was assessed at T1 to T4.
Time frame: Baseline (T1), Week 14 (T4)
Population: 1 Standard of Care participant missing data for this variable
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Patients | Mean Time Spent Sitting on the Weekdays | Baseline (T1) | 8.95 hours | Standard Deviation 3.44 |
| All Patients | Mean Time Spent Sitting on the Weekdays | Week 14 (T4) | 7.0 hours | Standard Deviation 2.28 |
| Standard of Care (SC) | Mean Time Spent Sitting on the Weekdays | Baseline (T1) | 6.57 hours | Standard Deviation 4.08 |
| Standard of Care (SC) | Mean Time Spent Sitting on the Weekdays | Week 14 (T4) | 7.0 hours | Standard Deviation 2.31 |
Mean Time Spent Sitting on the Weekends
Behavioral Risk Factor Surveillance System (BRFSS) items measured sedentarism as a health behavior - BRFSS Item What is the total number of hours you spend sitting on a weekend day? Mean ranges from a minimum of 0 to maximum of 24 hours. Average numbers of hours spent sitting on the weekends assessed at T1 and T4.
Time frame: Baseline (T1), Week 14 (T4)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Patients | Mean Time Spent Sitting on the Weekends | Baseline (T1) | 7.68 hours | Standard Deviation 3.53 |
| All Patients | Mean Time Spent Sitting on the Weekends | Week 14 (T4) | 4.22 hours | Standard Deviation 2.26 |
| Standard of Care (SC) | Mean Time Spent Sitting on the Weekends | Baseline (T1) | 6.0 hours | Standard Deviation 3.66 |
| Standard of Care (SC) | Mean Time Spent Sitting on the Weekends | Week 14 (T4) | 6.43 hours | Standard Deviation 3.1 |
Non-prescription Street Drug Use Total Mean Score
Surveys administered at baseline (T1) and Week 14 (T4) evaluated self-reported non-prescription street drug use in all participants. One item from the Substance Abuse and Mental Illness Symptoms Screener (SAMISS) Survey evaluated non-prescription street drug use in the last year. The response options ranged from a minimum of 0=Never to a maximum of 4=Daily/Almost Daily. Higher scores indicate higher consumption.
Time frame: Baseline (T1), Week 14 (T4)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Patients | Non-prescription Street Drug Use Total Mean Score | Baseline (T1) | 1.37 score on a scale | Standard Deviation 1.71 |
| All Patients | Non-prescription Street Drug Use Total Mean Score | Week 14 (T4) | 0.95 score on a scale | Standard Deviation 1.47 |
| Standard of Care (SC) | Non-prescription Street Drug Use Total Mean Score | Baseline (T1) | 0.88 score on a scale | Standard Deviation 1.36 |
| Standard of Care (SC) | Non-prescription Street Drug Use Total Mean Score | Week 14 (T4) | 0.13 score on a scale | Standard Deviation 0.35 |
Participant Satisfaction With VC-CBCS Intervention Mean Score
After each VC-CBCS intervention session, participants completed a 14-item acceptability/satisfaction survey about their impressions with the current intervention session. Items are scored on a scale from 1= not at all to 5=extremely useful. Data across all VC-CBCS participants and all intervention sessions were averaged into a Total Patient Satisfaction score that could range from a minimum of 1 to a maximum of 5 with higher scores indicating greater satisfaction.
Time frame: Baseline (T1) to Week 14 (T4)
Population: Participants randomized to Standard of Care received no intervention and did not complete survey.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| All Patients | Participant Satisfaction With VC-CBCS Intervention Mean Score | 4.23 score on a scale | Standard Deviation 0.5 |
Perceived Stress Mean Score
The Perceived Stress Scale (PSS) is a widely used survey to measure stress perception. The scale includes 10 items, rated using a 5-point scale, from 0 (never) to 4 (very often) where patients report the frequency of stress symptoms in the past month. Items are summed with a minimum and maximum ranging from 0 to 40. Higher PSS scores reflect higher subjective stress.
Time frame: Baseline (T1), Week 14 (T4)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| All Patients | Perceived Stress Mean Score | Baseline (T1) | 24.2 score on a scale |
| All Patients | Perceived Stress Mean Score | Week 14 (T4) | 20.6 score on a scale |
| Standard of Care (SC) | Perceived Stress Mean Score | Baseline (T1) | 23.9 score on a scale |
| Standard of Care (SC) | Perceived Stress Mean Score | Week 14 (T4) | 21.8 score on a scale |
Percentage of Overall Medication Adherence
Medication Adherence Visual Analog Scales (VAS) was used to evaluate medication adherence for up to five daily medications for multiple comorbidities in the past 7 days in participants who were prescribed medications at baseline. Participants reported the average adherence over the course of 7 days for each medication on a scale from 0% to 100% adherence for each medication. The average percent adherence was created for all medications for each patient and could range from 0% to 100%. Overall medication adherence adherence was assessed at T1 and T4.
Time frame: Baseline (T1), Week 14 (T4)
Population: 7 VC-CBCS Intervention participants were excluded from the analysis because they were not prescribed daily medications at Baseline (T1). Two of the 12 VC-CBCS participants and 4 of the Standard of Care participants were missing data for this variable at T4.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| All Patients | Percentage of Overall Medication Adherence | Baseline (T1) | 85.2 percentage of medication adherence |
| All Patients | Percentage of Overall Medication Adherence | Week 14 (T4) | 92.8 percentage of medication adherence |
| Standard of Care (SC) | Percentage of Overall Medication Adherence | Baseline (T1) | 96.9 percentage of medication adherence |
| Standard of Care (SC) | Percentage of Overall Medication Adherence | Week 14 (T4) | 89.8 percentage of medication adherence |
Percentage of Participants Who Complete Moderate Activity for at Least 10 Minutes at a Time
Behavioral Risk Factor Surveillance System (BRFSS) items measured moderate activity as a health behavior in all participants at T1 (baseline) and T4 (week 14) and will cover 30 days prior to assessment. BRFSS item asks Do you do moderate activity for at least 10 minutes at a time? Response options: Yes/No. Percentage is participants who indicate Yes to doing moderate activity for at least 10 minutes at a time
Time frame: Baseline (T1), Week 14 (T4)
Population: 1 VC-CBCS Intervention participant with missing data at T1.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| All Patients | Percentage of Participants Who Complete Moderate Activity for at Least 10 Minutes at a Time | Baseline (T1) | 73.7 percentage of participants |
| All Patients | Percentage of Participants Who Complete Moderate Activity for at Least 10 Minutes at a Time | Week 14 (T4) | 78.9 percentage of participants |
| Standard of Care (SC) | Percentage of Participants Who Complete Moderate Activity for at Least 10 Minutes at a Time | Baseline (T1) | 50.0 percentage of participants |
| Standard of Care (SC) | Percentage of Participants Who Complete Moderate Activity for at Least 10 Minutes at a Time | Week 14 (T4) | 87.5 percentage of participants |
Percentage of Participants Who Complete Vigorous Activity for at Least 10 Minutes at a Time
Behavioral Risk Factor Surveillance System (BRFSS) items measured vigorous activity as a health behavior - BRFSS Item Do you do vigorous activity for at least 10 minutes at a time? Response option: Yes/No. Percentage is participants who indicate Yes to doing vigorous activity for at least 10 minutes at a time
Time frame: Baseline (T1), Week 14 (T4)
Population: 1 VC-CBCS Intervention participant missing data for this variable
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| All Patients | Percentage of Participants Who Complete Vigorous Activity for at Least 10 Minutes at a Time | Baseline (T1) | 42.1 percentage of participants |
| All Patients | Percentage of Participants Who Complete Vigorous Activity for at Least 10 Minutes at a Time | Week 14 (T4) | 47.4 percentage of participants |
| Standard of Care (SC) | Percentage of Participants Who Complete Vigorous Activity for at Least 10 Minutes at a Time | Baseline (T1) | 50.0 percentage of participants |
| Standard of Care (SC) | Percentage of Participants Who Complete Vigorous Activity for at Least 10 Minutes at a Time | Week 14 (T4) | 25.0 percentage of participants |
Percentage of Participants Who Improved Fruit Consumption by One or More Categories
Behavioral Risk Factor Surveillance System (BRFSS) items assessed fruit intake as a health behavior - Over the past 12 months, how often did you eat fruits? Original 8-point response scale ranged from 1 time per month to 2 or more times/day. Recoded 8 categories into 4 categories, ranging from Daily consumption to Less than weekly. The percentage shown is the number of participants who improved by 1 or more categories based on the 4 category levels from T1 to T4.
Time frame: Baseline (T1) to Week 14 (T4)
Population: 1 Standard of Care participant missing data for this variable
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Patients | Percentage of Participants Who Improved Fruit Consumption by One or More Categories | 47.0 percentage of patients |
| Standard of Care (SC) | Percentage of Participants Who Improved Fruit Consumption by One or More Categories | 43.0 percentage of patients |
Percentage of Participants Who Improved Vegetable Consumption by One or More Categories
Behavioral Risk Factor Surveillance System (BRFSS) items measured vegetable intake as a health behavior - Over the past 12 months, how often did you eat vegetables? Original 8-point response scale ranged from 1 time per month to 2 or more times/day. Recoded 8 categories into 4 categories, ranging from Daily consumption to Less than weekly. The percentage is the number of participants who improved by 1 or more categories on the 4 category levels from T1 to T4.
Time frame: Baseline (T1) to Week 14 (T4)
Population: 1 Standard of Care participant missing data for this variable
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Patients | Percentage of Participants Who Improved Vegetable Consumption by One or More Categories | 16 percentage of participants |
| Standard of Care (SC) | Percentage of Participants Who Improved Vegetable Consumption by One or More Categories | 14 percentage of participants |
Percentage of Participants Who Increased Dinners Prepared at Home by 1 or More Days
Behavioral Risk Factor Surveillance System (BRFSS) items measured food prepared at home as a health behavior - BRFSS item On how many days per week do you usually eat a dinner that is prepared at home? 7-point response scale ranged from 0 to 7 days. The percentage is the number of patients who improved (increased) by 1 or more days from T1 to T4.
Time frame: Baseline (T1) to Week 14 (T4)
Population: Three participants were missing data for this variable (2 VC-CBCS Intervention participants, 1 Standard of Care participant)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Patients | Percentage of Participants Who Increased Dinners Prepared at Home by 1 or More Days | 35 percentage of participants |
| Standard of Care (SC) | Percentage of Participants Who Increased Dinners Prepared at Home by 1 or More Days | 0 percentage of participants |
Percentage of Participants Who Reduced Diet Soda Intake by One or More Categories
Behavioral Risk Factor Surveillance System (BRFSS) items measured diet soda intake as a health behavior - BRFSS item During the past 30 days, how often did you drink diet soda or diet pop that contains an artificial sweeter? Original 9-point response scale ranged from Never to 6 or more per day. Recoded 9 categories into 5, ranging from Never to Daily. The percentage is the number of patients who improved (consumed less) by 1 or more categories on the 5 recoded category level from T1 to T4.
Time frame: Baseline (T1) to Week 14 (T4)
Population: 2 Standard of Care participants missing data for this variable
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Patients | Percentage of Participants Who Reduced Diet Soda Intake by One or More Categories | 5 percentage of participants |
| Standard of Care (SC) | Percentage of Participants Who Reduced Diet Soda Intake by One or More Categories | 17 percentage of participants |
Percentage of Participants Who Reduced Fruit Juice Intake by One or More Categories
Behavioral Risk Factor Surveillance System (BRFSS) items measured fruit juice intake as a health behavior - BRFSS item During the past month, how many times per day, week or month did you drink 100% pure fruit juices? Original 9-point response scale ranged from Never to 6 or more per day. Recoded 9 categories into 5, ranging from Never to Daily. The percentage is the number of participants who improved (consumed less) by 1 or more categories on the 5 recoded category levels from T1 to T4.
Time frame: Baseline (T1) to Week 14 (T4)
Population: 1 Standard of Care participant missing data for this variable
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Patients | Percentage of Participants Who Reduced Fruit Juice Intake by One or More Categories | 16 percentage of participants |
| Standard of Care (SC) | Percentage of Participants Who Reduced Fruit Juice Intake by One or More Categories | 29 percentage of participants |
Percentage of Participants Who Reduced Meals From Fast Food Restaurants by One or More Categories
Behavioral Risk Factor Surveillance System (BRFSS) items measured fast food intake as a health behavior - BRFSS item In a typical week, how many of your own meals come from fast food restaurants? Original 9-point response scale ranged from Never to 6 or more per day. Recoded 9 categories into 5, ranging from Never to Daily. The percentage is the number of participants who improved (reduced) by 1 or more categories on the 5 recoded category levels from T1 to T4.
Time frame: Baseline (T1) to Week 14 (T4)
Population: 3 participants were missing data for this variable (1 VC-CBCS Intervention participant, 2 Standard of Care participants)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Patients | Percentage of Participants Who Reduced Meals From Fast Food Restaurants by One or More Categories | 39 percentage of participants |
| Standard of Care (SC) | Percentage of Participants Who Reduced Meals From Fast Food Restaurants by One or More Categories | 17 percentage of participants |
Percentage of Participants Who Reduced Regular Soda Intake by One or More Categories
Behavioral Risk Factor Surveillance System (BRFSS) items measured soda intake as a health behavior - BRFSS item During the past 30 days, how often did you drink regular soda or pop that contains sugar? Do not include diet soda or diet pop. Original 9-point response scale ranged from Never to 6 more more per day. Recoded 9 categories into 5 categories, ranging from Never to Daily. The percentage is the number of participants who improved (consumed less) by 1 or more categories on the 5 category levels from T1 to T4.
Time frame: Baseline (T1) to Week 14 (T4)
Population: 3 participants missing data for this variable (2 VC-CBCS Intervention participants, 1 Standard of Care participant)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Patients | Percentage of Participants Who Reduced Regular Soda Intake by One or More Categories | 35 percentage of participants |
| Standard of Care (SC) | Percentage of Participants Who Reduced Regular Soda Intake by One or More Categories | 14 percentage of participants |
Pittsburgh Sleep Quality Index (PSQI) Sleep Efficiency Composite Mean Score
Items 1, 3 and 4 from the Pittsburgh Sleep Quality Index (PSQI) were used to create a Sleep Efficiency composite score. All participants completed this measure at T1 and T4 that covered 30 days prior to assessment. The sleep efficiency score = (# hours slept/# hours in bed) X 100% .The sleep efficiency composite score ranged from: 0 = \>85% efficiency, 1 = 75-84% efficiency, 2= 65-74% efficiency, and 3= \<65%. Lower scores indicate better sleep efficiency.
Time frame: Baseline (T1), Week 14 (T4)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Patients | Pittsburgh Sleep Quality Index (PSQI) Sleep Efficiency Composite Mean Score | Baseline (T1) | 1.05 score on a scale | Standard Deviation 1.22 |
| All Patients | Pittsburgh Sleep Quality Index (PSQI) Sleep Efficiency Composite Mean Score | Week 14 (T4) | 1.26 score on a scale | Standard Deviation 1.37 |
| Standard of Care (SC) | Pittsburgh Sleep Quality Index (PSQI) Sleep Efficiency Composite Mean Score | Baseline (T1) | 1.38 score on a scale | Standard Deviation 1.3 |
| Standard of Care (SC) | Pittsburgh Sleep Quality Index (PSQI) Sleep Efficiency Composite Mean Score | Week 14 (T4) | 0.75 score on a scale | Standard Deviation 1.04 |
Pittsburgh Sleep Quality Index (PSQI) Sleep Quality Mean Score
Item 9 from the Pittsburgh Sleep Quality Index (PSQI) was used to measure sleep quality. All participants completed this measure at PRO time points T1 and T4 that covered 30 days prior to assessment. During the past month, how would you rate your sleep quality overall? The response set ranged from a minimum of 0 (Very Good) to a maximum of 3 (Very Bad). Higher scores indicated worse sleep quality.
Time frame: Baseline (T1), Week 14 (T4)
Population: 1 Standard of Care participant missing data for this variable at T4
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Patients | Pittsburgh Sleep Quality Index (PSQI) Sleep Quality Mean Score | Baseline (T1) | 1.32 score on a scale | Standard Deviation 0.82 |
| All Patients | Pittsburgh Sleep Quality Index (PSQI) Sleep Quality Mean Score | Week 14 (T4) | 1.05 score on a scale | Standard Deviation 0.52 |
| Standard of Care (SC) | Pittsburgh Sleep Quality Index (PSQI) Sleep Quality Mean Score | Baseline (T1) | 1.13 score on a scale | Standard Deviation 0.64 |
| Standard of Care (SC) | Pittsburgh Sleep Quality Index (PSQI) Sleep Quality Mean Score | Week 14 (T4) | 0.71 score on a scale | Standard Deviation 0.76 |
Prescription Drug Misuse Total Mean Score
Surveys administered at baseline (T1) and Week 14 (T4) evaluated self-reported prescription drug misuse in all participants. One item from the Substance Abuse and Mental Illness Symptoms Screener (SAMISS) Survey evaluated misuse of prescription drugs in the last year. The response options ranged from a minimum of 0=Never to a maximum of 4=Daily/Almost Daily. Higher scores indicate higher consumption.
Time frame: Baseline (T1), Week 14 (T4)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Patients | Prescription Drug Misuse Total Mean Score | Baseline (T1) | 0.11 score on a scale | Standard Deviation 0.32 |
| All Patients | Prescription Drug Misuse Total Mean Score | Week 14 (T4) | 0.11 score on a scale | Standard Deviation 0.32 |
| Standard of Care (SC) | Prescription Drug Misuse Total Mean Score | Baseline (T1) | 0.0 score on a scale | Standard Deviation 0 |
| Standard of Care (SC) | Prescription Drug Misuse Total Mean Score | Week 14 (T4) | 0.0 score on a scale | Standard Deviation 0 |
Participant Satisfaction With VC-CBCS Telehealth Session Mean Score
After intervention week 1 and week 14, participants in the VC-CBCS intervention completed a 15-item acceptability/satisfaction survey about their satisfaction with using telehealth sessions. Items were scored on a scale from 1= strongly disagree to 5=strongly agree. The average Total Telehealth Satisfaction score from week 1 and week 14 was created, which ranged from 1 to 5 with higher scores indicating greater satisfaction. A previously developed Telehealth Patient Satisfaction Questionnaire was modified for this study.
Time frame: Baseline (T1) to Week 14 (T4)
Population: Participants randomized to Standard of Care received no intervention and did not complete survey.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Patients | Participant Satisfaction With VC-CBCS Telehealth Session Mean Score | Week 1 | 3.91 score on a scale | Standard Deviation 0.68 |
| All Patients | Participant Satisfaction With VC-CBCS Telehealth Session Mean Score | Week 14 | 4.5 score on a scale | Standard Deviation 0.38 |
Salivary Cortisol Area Under the Curve With Respect to Ground (AUC-G)
Participants in both conditions collected saliva samples at Baseline (T1) and Week 14 (T4). Participants were instructed to collect four saliva samples at each timepoint; 1) immediately upon awakening 2) 30 minutes after awakening 3) late afternoon 4) before bedtime. The mean AUC-G was then obtained at T1 and T4. Mean AUC-G scores could range from 0.195 to 2.29.
Time frame: Baseline (T1), Week 14 (T4)
Population: T1: Data from 1 Standard of Care participant were excluded due to nontraditional sleep schedule. Data from 5 VC-CBCS Intervention participants were excluded due to missing data, nontraditional sleep schedules, and/or noncompliance with sample collection instructions.~T4: Data from 2 Standard of Care participants and 7 VC-CBCS Intervention participants were excluded due to missing data, nontraditional sleep schedules, and/or noncompliance with sample collection instructions.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Patients | Salivary Cortisol Area Under the Curve With Respect to Ground (AUC-G) | Baseline (T1) | 1.01 ug/dL | Standard Deviation 0.54 |
| All Patients | Salivary Cortisol Area Under the Curve With Respect to Ground (AUC-G) | Week 14 (T4) | 0.71 ug/dL | Standard Deviation 0.23 |
| Standard of Care (SC) | Salivary Cortisol Area Under the Curve With Respect to Ground (AUC-G) | Baseline (T1) | 1.18 ug/dL | Standard Deviation 0.65 |
| Standard of Care (SC) | Salivary Cortisol Area Under the Curve With Respect to Ground (AUC-G) | Week 14 (T4) | 0.83 ug/dL | Standard Deviation 0.46 |